Genomic description of acquired fluconazole- and echinocandin-resistance in patients with serial Candida glabrata isolates.

E Misas, E Seagle, E N Jenkins, M Rajeev, S Hurst, N S Nunnally, M L Bentz, M M Lyman, E Berkow, L H Harrison, W Schaffner, T M Markus, R Pierce, M M Farley, N A Chow, S R Lockhart, A P Litvintseva

Journal of clinical microbiology 2024 Feb 14

filter terms:

Candida glabrata is one of the most common causes of systemic candidiasis, often resistant to antifungal medications. To describe the genomic context of emerging resistance, we conducted a retrospective analysis of 82 serially collected isolates from 33 patients from population-based candidemia surveillance in the United States. We used whole-genome sequencing to determine the genetic relationships between isolates obtained from the same patient. Phylogenetic analysis demonstrated that isolates from 29 patients were clustered by patient. The median SNPs between isolates from the same patient was 30 (range: 7-96 SNPs), while unrelated strains infected four patients. Twenty-one isolates were resistant to echinocandins, and 24 were resistant to fluconazole. All echinocandin-resistant isolates carried a mutation either in the FKS1 or FKS2 HS1 region. Of the 24 fluconazole-resistant isolates, 17 (71%) had non-synonymous polymorphisms in the PDR1 gene, which were absent in susceptible isolates. In 11 patients, a genetically related resistant isolate was collected after recovering susceptible isolates, indicating in vivo acquisition of resistance. These findings allowed us to estimate the intra-host diversity of C. glabrata and propose an upper boundary of 96 SNPs for defining genetically related isolates, which can be used to assess donor-to-host transmission, nosocomial transmission, or acquired resistance. IMPORTANCE In our study, mutations associated to azole resistance and echinocandin resistance were detected in Candida glabrata isolates using a whole-genome sequence. C. glabrata is the second most common cause of candidemia in the United States, which rapidly acquires resistance to antifungals, in vitro and in vivo.

Citation

E Misas, E Seagle, E N Jenkins, M Rajeev, S Hurst, N S Nunnally, M L Bentz, M M Lyman, E Berkow, L H Harrison, W Schaffner, T M Markus, R Pierce, M M Farley, N A Chow, S R Lockhart, A P Litvintseva. Genomic description of acquired fluconazole- and echinocandin-resistance in patients with serial Candida glabrata isolates. Journal of clinical microbiology. 2024 Feb 14;62(2):e0114023